Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer

David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses potential TRK inhibitors that could be used in the treatment of patients with thyroid cancer after the approval of larotrectinib (Vitrakvi). Overall, a significant amount of patients seem to respond to larotrectinib and the responses appear very durable, Hong says. The hope with LOXO-195, another TRK inhibitor, is to see more of these significant responses and durability in these patients. Like many other small molecules, next steps include determining the mechanisms of resistance and if other drugs can be developed that are less toxic. Larotrectinib and entrectinib are relatively non-toxic drugs, says Hong, but the unique side effects must also be determined. These are questions investigators are currently exploring in the field. For more resources and information regarding anticancer targeted therapies in thyroid cancer: http://targetedonc.com/resource-cente...